Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant [Phase 1]
Phase 1 trial evaluating emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil to prevent graft-versus-host…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML [Phase 2]
Phase 2 clinical trial update comparing HAV versus DAV/IAV induction regimens in elderly patients with acute myeloid leukemia.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]
Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host dise…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with NPM1-…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML [Phase 3]
A Phase 3 trial is evaluating whether an intermediate-dose cytarabine induction regimen improves outcomes in adults with acute myeloid leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
A clinical trial exploring c-KIT mutation as minimal residual disease (MRD) in acute myeloid leukemia. It is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating the combination of selinexor, venetoclax, and azacitidine in newly diagnosed acute myeloid leukemia …
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy [NA]
Clinical trial update showing ongoing recruitment to optimize induction chemotherapy regimens for newly diagnosed elderly patients with acut…
-
CLINICAL_TRIALS withdrawal · 2025-05-30Clinical Trial Update: Efficacy of Decitabine in Clearance of MRD [Phase 1, Phase 2]
A phase 1/2 trial evaluating decitabine for clearance of minimal residual disease in acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment [Phase 2]
A Phase 2 trial is evaluating gilteritinib in combination with venetoclax and azacitidine for FLT3-mutated acute myeloid leukemia patients i…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Use of Venetoclax , AML , Sohag , Egypt
A clinical trial evaluating venetoclax for acute myeloid leukemia at Sohag University in Egypt has completed.
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) [Phase 1]
An early-phase clinical trial evaluating Tagraxofusp as post-transplant maintenance in patients with CD123-positive acute myeloid leukemia, …
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study evaluating LYT-200 in adults with relapsed/refractory acute myeloid leukemia or relapsed/refractory high-risk myelodysplastic …
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]
A Phase 1 study evaluating multi-antigen specific CD8+ T cells with decitabine and lymphodepleting chemotherapy for relapsed or refractory a…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study of JNJ-67571244 in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 study of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in relapsed or refractory acute myeloid leukemia or acut…
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant [Phase 1, Phase 2]
A Phase 1/2 trial evaluating daratumumab plus donor lymphocyte infusion in relapsed acute myeloid leukemia after stem cell transplantation w…
-
FDA approval · 2025-05-20FDA Approved: AZACITIDINE — Original Application (Reliance Life Sciences Private Limited)
FDA approved the original application for azacitidine by Reliance Life Sciences Private Limited (ANDA217453), authorizing a generic version …
-
CLINICAL_TRIALS research · 2025-05-20Clinical Trial Update: XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia [EARLY_Phase 1]
This early-phase 1 trial update covers XP-005, a personalized cancer vaccine used alone or in combination with toripalimab for preventing re…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS [Phase 2]
Phase 2 trial evaluating BST-236 as a single-agent therapy in adults with relapsed or refractory acute myeloid leukemia or high-risk myelody…
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial is evaluating a conditioning regimen combining thiotepa, busulfan, and fludarabine for haploidentical hematopoietic…
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML [Phase 1, Phase 2]
Clinical trial update showing CFI-400945 with or without azacitidine is being studied in acute myeloid leukemia, myelodysplastic syndromes, …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial update for the IDH2 inhibitor AG-221 (enasidenib) in IDH2-mutated myelodysplastic syndrome; the study is active but n…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome [Phase 2]
Phase 2 trial of the IDH1 inhibitor ivosidenib (AG-120) in IDH1-mutated myelodysplastic syndromes (also listed for acute myeloid leukemia); …
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS [Phase 1]
A Phase 1 study from Novartis evaluating PDR001 and MBG453 with decitabine in acute myeloid leukemia or high-risk myelodysplastic syndromes …